GREAT TREE PHARMACY CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 279.5 TWD | -1.41% |
|
-0.53% | -20.03% |
| 03-04 | Great Tree Pharmacy Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 02-27 | Great Tree Pharmacy Co., Ltd. Cash Dividend for the Year 2023 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 57% by 2026.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company does not generate enough profits, which is an alarming weak point.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 42.62 times its estimated earnings per share for the ongoing year.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Drug Retailers
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -20.03% | 984M | - | ||
| -13.23% | 3.49B | D+ | ||
| -6.66% | 3.17B | D- | ||
| -24.46% | 3.13B | D | ||
| +21.34% | 2.9B | C+ | ||
| -8.42% | 1.78B | - | ||
| +10.93% | 1.4B | - | - | |
| -37.30% | 707M | - | - | |
| -0.53% | 460M | - | D+ | |
| +5.39% | 403M | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 6469 Stock
- Ratings Great Tree Pharmacy Co., Ltd.